The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study

References

• Roda G, Chien Ng S, Kotze PG, et al. Crohn’s disease. Nat Rev Dis Primers. 2020;6(1):22.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517.
   PubMed Web of Science ®Google Scholar
• GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30. doi: 10.1016/s2468-1253(19)30333-4.
   PubMed Web of Science ®Google Scholar
• Xu F, Dahlhamer JM, Zammitti EP, et al. Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease - United States, 2015 and 2016. MMWR Morb Mortal Wkly Rep. 2018;67(6):190–195.
   PubMed Web of Science ®Google Scholar
• Xu F, Carlson S, Liu Y, et al. Prevalence of inflammatory bowel disease among medicare fee-for-service beneficiaries - United States, 2001–2018. MMWR Morb Mortal Wkly Rep. 2021; 70(19):698–701. doi: 10.15585/mmwr.mm7019a2.
   PubMed Web of Science ®Google Scholar
• Ganz ML, Sugarman R, Wang R, et al. The economic and health-related impact of Crohn’s disease in the United States: evidence from a nationally representative survey. Inflamm Bowel Dis. 2016;22(5):1032–1041. doi: 10.1097/mib.0000000000000742.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Shahabi A, Seabury SA, et al. Lifetime economic burden of Crohn’s disease and ulcerative colitis by age at diagnosis. Clin Gastroenterol Hepatol. 2020;18(4):889–897.e10.
   PubMed Web of Science ®Google Scholar
• Manceur AM, Ding Z, Muser E, et al. Burden of Crohn’s DIsease in the United States: long-term healthcare and work-loss related costs. J Med Econ. 2020;23(10):1092–1101.
   PubMed Web of Science ®Google Scholar
• Sulz MC, Burri E, Michetti P, et al. Treatment algorithms for Crohn’s Disease. Digestion. 2020;101(Suppl 1):43–57.
   PubMed Web of Science ®Google Scholar
• Dunleavy KA, Pardi DS. Biologics: how far can they go in Crohn’s disease? Gastroenterol Rep . 2022;10:goac049.
   Google Scholar
• Samaan M, Campbell S, Cunningham G, et al. Biologic therapies for Crohn’s disease: optimising the old and maximising the new. F1000Res. 2019;8:8.
   PubMedGoogle Scholar
• Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn’s disease in the United States. PLOS One. 2017;12(4):e0175099.
   PubMed Web of Science ®Google Scholar
• Khan S, Rupniewska E, Neighbors M, et al. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507.
   PubMed Web of Science ®Google Scholar
• Perry J, Chen A, Kariyawasam V, et al. Medication non-adherence in inflammatory bowel diseases is associated with disability. Intest Res. 2018;16(4):571–578.
   PubMedGoogle Scholar
• Pilon D, Ding Z, Muser E, et al. Indicators of suboptimal treatment and associated healthcare costs among patients with Crohn’s disease initiated on biologic or conventional agents. Crohns Colitis 360. 2022;4(3):otac021.
   PubMedGoogle Scholar
• Merative™ MarketScan® Research Databases. 2023. Available from: https://www.merative.com/documents/brief/marketscan-explainer-general.
   Google Scholar
• Perera S, Yang S, Stott-Miller M, et al. Analysis of healthcare resource utilization and costs after the initiation of biologic treatment in patients with ulcerative colitis and Crohn’s disease. J Health Econ Outcomes Res. 2018;6(1):96–112.
   PubMedGoogle Scholar
• Rubin DT, Mody R, Davis KL, et al. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn’s disease. Aliment Pharmacol Ther. 2014;39(10):1143–1155.
   PubMed Web of Science ®Google Scholar
• Chen G, Lissoos T, Dieyi C, et al. Development and validation of an inflammatory bowel disease severity index using US administrative claims data: a retrospective cohort study. Inflamm Bowel Dis. 2021;27(8):1177–1183.
   PubMed Web of Science ®Google Scholar
• Lee KE, Tu VY, Faye AS. Optimal management of refractory Crohn’s disease: current landscape and future direction. Clin Exp Gastroenterol. 2024;17:75–86.
   PubMed Web of Science ®Google Scholar
• Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011; 106(4):674–684.
   PubMed Web of Science ®Google Scholar
• Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417–1427.
   PubMed Web of Science ®Google Scholar
• Chiorean M, Afzali A, Cross RK, et al. Economic outcomes of inflammatory bowel disease patients switching to a second anti-tumor necrosis factor or vedolizumab. Crohns Colitis 360. 2020;2(2):otaa031.
   PubMedGoogle Scholar
• Kawalec P, Moćko P. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn’s disease patients. J Comp Eff Res. 2018; 7(2):101–111.
   PubMed Web of Science ®Google Scholar
• Manlay L, Boschetti G, Pereira B, et al. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor therapy. Aliment Pharmacol Ther. 2021;53(12):1289–1299.
   PubMed Web of Science ®Google Scholar
• Volkers A, Straatmijer T, Duijvestein M, et al. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Aliment Pharmacol Ther. 2022;56(6):1044–1054.
   PubMed Web of Science ®Google Scholar
• Bressler B. Is there an optimal sequence of biologic therapies for inflammatory bowel disease? Therap Adv Gastroenterol. 2023;16:17562848231159452.
   Web of Science ®Google Scholar
• Alliance for Patient Access. A study of the qualitative impact of non-medical switching. Washington DC: Alliance for Patient Access; 2019.
   Google Scholar
• Salam T, Duhig A, Patel AA, et al. Physicians’ perspectives regarding non-medical switching of prescription medications: results of an internet e-survey. PLOS One. 2020;15(1):e0225867.
   PubMed Web of Science ®Google Scholar
• Institute for Patient Access. Cost-motivated treatment changes & non-medical switching - commercial health plans analysis. Washington DC: Alliance for Patient Access; 2017.
   Google Scholar
• Costa OS, Salam T, Duhig A, et al. Specialist physician perspectives on non-medical switching of prescription medications. J Mark Access Health Policy. 2020;8(1):1738637.
   PubMedGoogle Scholar
• Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(5):415–427. doi: 10.1016/S2468-1253(24)00034-7.
   PubMed Web of Science ®Google Scholar